Skip to main content

Table 2 Number of events and rates of included randomised controlled trials

From: Cardiovascular and mortality events in type 2 diabetes cardiovascular outcomes trials: a systematic review with trend analysis

Randomised controlled trial (RCT) All-cause mortality Cardiovascular disease mortality Major adverse cardiovascular eventsa Total myocardial infarction Nonfatal myocardial infarction Total stroke Nonfatal stroke
n Rate n Rate n Rate n Rate n Rate n Rate n Rate
UGDP 21 14.6 10 7.0
UKPDS 33 213 18.9 186 17.4 101 9.5 55 5.0 44 4.0
DCGP 147 48.0 75 27.3 50 17.4
STENO-2 15 24.0 7 11.2 17 27.2 20 32.1
JDCS 43 5.4 75 9.5
VADT 95 18.9 29 5.8 78 15.5 36 7.2
PROactive 186 24.5 144 19.0 107 14.1
LOOK AHEAD 202 8.6 57 2.4 283 12.5 191 8.4 183 8.0 80 3.4
RECORD 157 12.8 71 5.8 165 13.5 56 4.6 63 5.1
ADVANCE 533 19.1 590 21.2 337 12.1 246 8.8
ACCORD 203 11.4 94 5.6 371 22.9 235 14.5 61 3.7
ADDITION 92 12.5
HEART2D 102 33.9 86 28.6 126 41.9 103 34.2 37 12.3 35 11.6
ORIGIN 965 26.0 576 15.5 1013 28.5 326 9.0 319 8.8
TECOS 537 24.5 366 16.7 746 36.2 316 15.1 183 8.7
TOSCA 105 7.5 45 3.0 40 2.5
EXAMINE 173 43.1 130 32.4 316 78.6
CANVAS 307 19.5 201 12.8 496 31.5 198 12.6 183 11.6 151 9.6 132 8.4
SAVOR-TIMI 378 21.0 260 14.5 609 36.0 278 17.0
LEADER 447 25.0 278 16.0 694 39.0 339 19.0 317 18.0 199 11.0 177 10.0
ALECARDIO 138 19.1 98 13.6 360 49.9 239 33.1 50 6.9
ELIXA 223 33.0 158 24.0 261 41.0 60 9.0
EMPAREG 194 28.6 137 20.2 282 43.9 69 10.5 60 9.1
EXSCEL 584 23.0 383 15.0 905 40.0 493 21.0 218 9.0
SUSTAIN-6 60 17.6 46 13.5 146 44.0 64 19.2 44 13.1
DEVOTE 423 28.0 278 18.4 681 45.0 313 23.7 150 10.7
  1. Trials are listed by starting calendar year (older to newer) and number of participants (largest to smallest); their references are reported in the supplementary material. Data shown for control arm (except DEVOTE, TOSCA, HEART2D where arms were combined)
  2. n number of events; rate are per 1000 person-years
  3. a3-Point major adverse cardiovascular events: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke (details are reported in Supplementary Table S3)